dc.contributor.author
Röhr, Christina
dc.contributor.author
Kerick, Martin
dc.contributor.author
Fischer, Axel
dc.contributor.author
Kühn, Alexander
dc.contributor.author
Kashofer, Karl
dc.contributor.author
Timmermann, Bernd
dc.contributor.author
Daskalaki, Andriani
dc.contributor.author
Meinel, Thomas
dc.contributor.author
Drichel, Dmitriy
dc.contributor.author
Börno, Stefan T.
dc.contributor.author
Nowka, Anja
dc.contributor.author
Krobitsch, Sylvia
dc.contributor.author
McHardy, Alice C.
dc.contributor.author
Kratsch, Christina
dc.contributor.author
Becker, Tim
dc.contributor.author
Wunderlich, Andrea
dc.contributor.author
Barmeyer, Christian
dc.contributor.author
Viertler, Christian
dc.contributor.author
Zatloukal, Kurt
dc.contributor.author
Wierling, Christoph
dc.contributor.author
Lehrach, Hans
dc.contributor.author
Schweiger, Michal R.
dc.date.accessioned
2018-06-08T03:29:22Z
dc.date.available
2015-11-23T13:02:06.540Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/15288
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-19476
dc.description.abstract
MiRNAs are discussed as diagnostic and therapeutic molecules. However,
effective miRNA drug treatments with miRNAs are, so far, hampered by the
complexity of the miRNA networks. To identify potential miRNA drugs in
colorectal cancer, we profiled miRNA and mRNA expression in matching normal,
tumor and metastasis tissues of eight patients by Illumina sequencing. We
validated six miRNAs in a large tissue screen containing 16 additional tumor
entities and identified miRNA-1, miRNA-129, miRNA-497 and miRNA-215 as
constantly de-regulated within the majority of cancers. Of these, we
investigated miRNA-1 as representative in a systems-biology simulation of
cellular cancer models implemented in PyBioS and assessed the effects of
depletion as well as overexpression in terms of miRNA-1 as a potential
treatment option. In this system, miRNA-1 treatment reverted the disease
phenotype with different effectiveness among the patients. Scoring the gene
expression changes obtained through mRNA-Seq from the same patients we show
that the combination of deep sequencing and systems biological modeling can
help to identify patient-specific responses to miRNA treatments. We present
this data as guideline for future pre-clinical assessments of new and
personalized therapeutic options.
en
dc.rights.uri
http://creativecommons.org/licenses/by/2.0/de/
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit
dc.title
High-Throughput miRNA and mRNA Sequencing of Paired Colorectal Normal, Tumor
and Metastasis Tissues and Bioinformatic Modeling of miRNA-1 Therapeutic
Applications
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation
PLoS ONE. - 8 (2013), 7, Artikel Nr. e67461
dcterms.bibliographicCitation.doi
10.1371/journal.pone.0067461
dcterms.bibliographicCitation.url
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0067461
refubium.affiliation
Charité - Universitätsmedizin Berlin
de
refubium.mycore.fudocsId
FUDOCS_document_000000023516
refubium.note.author
Der Artikel wurde in einer Open-Access-Zeitschrift publiziert.
refubium.resourceType.isindependentpub
no
refubium.mycore.derivateId
FUDOCS_derivate_000000005703
dcterms.accessRights.openaire
open access